. 2023 Feb 13;14:809. doi: 10.1038/s41467-023-36370-x

Table 2.

Clinical responses to bortezomib and vorinostat containing salvage regimens

Case	Phenotype^a	Chemo doses		Pre-treament		Post-treatment
		Bortezomib^b	Vorinostat^b	%Blast^c	%MRD^c	%Blast^c	%MRD^c	Response^d
1	ALL	4	0	75	94.9	1	3.23	CRi
2	ALL	4	0	>90	ND	12	7.93	PRi
3a^e	ALL	6	0	83	86	0	1.38	CR
3b^e	ALL	8	12	83	ND	2	<0.01	CRi
4	ALL	6	12	74	67	60	48.14	SD
5	AML	8	12	52	68	0	2	CR
6^f	AML	8	12	46	23	26	<0.01	CRi
7	AML	6	12	8	5.87	2	<0.01	CR
8	AML	8	16	8	12.8	0	0.28	CRi
9	MPAL	6	12	86	78	0	0.997	CRi
10	ALL	8	16	46	30.8	0	<0.01	CR

MPAL mixed phenotype acute leukemia.

^aImmunophenotype by flow cytometry.

^bTotal number of doses of bortezomib and vorinostat given over the course of the treatment. All patients received two doses of mitoxantrone and additional chemo as described in Supplementary Table 5.

^cBlast percentage as determined by morphology; MRD percentage as determined by flow cytometry.

^dCR (complete response), CRi (complete response with incomplete blood count recovery), PRi (partial response with incomplete blood count recovery), SD (stable disease).

^eCase 3a course was pre-transplant, case 3b is the same patient course given post-transplant.

^fCase 6 had a systemic adenoviral infection prior to and post chemotherapy. At the time of evaluation post treatment, while morphologic blasts were elevated, this was felt to be a recovering marrow given negative MRD result by flow and PCR.